These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. Miname MH; Santos RD Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498 [TBL] [Abstract][Full Text] [Related]
28. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. Wójcik C Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791 [TBL] [Abstract][Full Text] [Related]
29. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. Hess CN; Low Wang CC; Hiatt WR Annu Rev Med; 2018 Jan; 69():133-145. PubMed ID: 29095667 [TBL] [Abstract][Full Text] [Related]
30. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. Jia X; Al Rifai M; Birnbaum Y; Smith SC; Virani SS Curr Atheroscler Rep; 2019 Apr; 21(6):20. PubMed ID: 30941517 [TBL] [Abstract][Full Text] [Related]
31. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
32. Keep recycling going: New approaches to reduce LDL-C. Klein-Szanto AJP; Bassi DE Biochem Pharmacol; 2019 Jun; 164():336-341. PubMed ID: 30953636 [TBL] [Abstract][Full Text] [Related]
33. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC J Am Coll Cardiol; 2017 Oct; 70(14):1785-1822. PubMed ID: 28886926 [TBL] [Abstract][Full Text] [Related]
35. HDL-C: role as a risk modifier. Barter P Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280 [TBL] [Abstract][Full Text] [Related]
36. Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon? Surma S; Sahebkar A; Banach M Curr Atheroscler Rep; 2024 Mar; 26(3):59-71. PubMed ID: 38165521 [TBL] [Abstract][Full Text] [Related]
37. Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go? Qamar A; Libby P Curr Cardiol Rep; 2019 Jun; 21(8):77. PubMed ID: 31250329 [TBL] [Abstract][Full Text] [Related]
38. Determining When to Add Nonstatin Therapy: A Quantitative Approach. Robinson JG; Huijgen R; Ray K; Persons J; Kastelein JJ; Pencina MJ J Am Coll Cardiol; 2016 Dec; 68(22):2412-2421. PubMed ID: 27908345 [TBL] [Abstract][Full Text] [Related]
39. The potential role of anti-PCSK9 monoclonal antibodies in the management of hypercholesterolemia. Lepor NE; Contreras L; Desai C; Kereiakes DJ Rev Cardiovasc Med; 2014; 15(4):290-307; quiz 308-9. PubMed ID: 25662924 [TBL] [Abstract][Full Text] [Related]
40. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations. Adhyaru BB; Jacobson TA Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]